Skip to main content

Proven safety profile.

Studied in the largest and longest clinical trial for hemophilia A.

Proven safety profile.

Studied in the largest and longest clinical trial for hemophilia A.

A thorough assessment.

Esperoct® is the result of a multi-year clinical trial shown to provide a safe and effective routine prophylaxis when administered every 4 days in adults, or twice weekly in children.

  • 0 blood clots in 270 previously treated patients
  • 0 PEG-related safety concerns
  • 1 previously treated patient with a high-risk gene mutation developed an inhibitor to Esperoct®a
    • Similar to the reported rate in patients with severe hemophilia A

aAn 18-year-old African-American male developed an inhibitor after 93 infusion days of Esperoct®. The inhibitor rose to 13.5 Bethesda units and the patient stopped participation in the study. There was no change in efficacy, and the inhibitor eventually went away on its own (without use of immune tolerance induction therapy).


A look at side effects.

During the Esperoct® clinical trial, the most commonly reported adverse reactions were:


A product that can take the heat.

The Esperoct® difference means you can store your factor at or below 104˚ for up to 3 months, opening the door to more of life’s adventures. Read about storage

Esperoct® storage temperature - Large
Esperoct® storage temperature - Large
Esperoct® drug molecule - PEGylation
Esperoct® drug molecule - PEGylation

Answering your PEG-related questions.

PEGylation is the technology behind Esperoct’s® extended half-life formula. Learn about PEG

Answering your PEG-related questions.

PEGylation is the technology behind Esperoct’s® extended half-life formula.
Learn about PEG

Manufactured in the U.S. with exacting standards.

The Novo Nordisk manufacturing principles make product safety the centerpiece of our efforts—from development to delivery.

With your safety as our guide, we commit to purity in every step of the Esperoct® process.

You count on us to make sure your factor is available when you need it. And we do.

Our well-established manufacturing process means you can rely on the same safe product with every infusion.

Esperoct® is made under tight control measures with quality our number one priority.

Purity

With your safety as our guide, we commit to purity in every step of the Esperoct® process.

Reliability

You count on us to make sure your factor is available when you need it. And we do.

Consistency

Our well-established manufacturing process means you can rely on the same safe product with every infusion.

Quality

Esperoct® is made under tight control measures with quality our number one priority.

Hemophilia Community Liaisons

HCL Connect.

Meet your Hemophilia Community Liaison (HCL)—here to help you at each step of your Esperoct® journey.

Esperoct® email newsletter

Receive email support.

Sign up to receive product information, community news, and helpful tips for living life with hemophilia.

Esperoct® FAQs
Esperoct® FAQs

Your questions, answered.

Question: When you say the “largest and longest clinical trial in hemophilia A,” what does that mean?

Answer: Let’s look at the numbers of the Pathfinder clinical program, research that evaluated Esperoct®:

  • In 270 previously treated people with severe hemophilia A
  • During five, multi-center clinical trials
  • Over 80,425 exposure days (corresponding to 889 patient years of treatment)

Beyond the numbers, the sheer breadth of the Pathfinder trial reflects the Novo Nordisk commitment to purity, reliability, consistency and quality. We understand how important these values are to the bleeding disorder community. The Pathfinder clinical trial represents our dedication to your safety, as well as the effectiveness of Esperoct®.

Question: What is an “exposure day” and why is it an important safety consideration for factor VIII products?

Answer: An “exposure day” (ED) is typically considered a unit of time (1 day) during which a patient receives replacement treatment. Considering EDs during a clinical trial is helpful since inhibitors typically develop in those with severe hemophilia A after a median treatment time of 10-15 days. After 50-75 EDs, the cumulative incidence of inhibitors plateaus. However, EDs don’t tell the whole story. Other considerations that affect safety considerations include the amount of factor, frequency of infusions, the type of factor concentrate, and more.

Selected Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face
What should I tell my healthcare provider before using Esperoct®?
  • Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®
What are the possible side effects of Esperoct®?
  • Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Prescribing Information.

Esperoct® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.